Merit Medical Q4 2022 revenue $293.4M (+5.4% YoY); GAAP EPS $0.58 vs $0.36; issues FY2023 guidance

MERIT MEDICAL SYSTEMS INC

2022-FY EPS reported $1.29 revenue$1,150,981,000

Q4 revenue $293.4M, up 5.4% YoY; constant currency organic revenue up 8.2%.
GAAP operating margin 10.4% (vs 7.9% Q4 2021); non-GAAP operating margin 17.8% (vs 17.4%).
GAAP EPS $0.58 (vs $0.36); non-GAAP EPS $0.79 (vs $0.71).
Issued fiscal year 2023 guidance; specific numbers not disclosed in excerpt.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MERIT MEDICAL SYSTEMS INC reported the fourth quarter ended December 31, 2022 results: revenue $293.4 million, EPS $0.58. Guidance initiated.

Period: the fourth quarter ended December 31, 2022
Revenue: $293.4 million
EPS: $0.58
Guidance: initiated
Result: reported results

Exact text from the filing

● Q4 2022 reported revenue of $293.4 million, up 5.4% compared to Q4 2021 ● Q4 2022 constant currency revenue, organic* up 8.2% compared to Q4 2021 ● Q4 2022 GAAP operating margin of 10.4%, compared to 7.9% in Q4 2021 ● Q4 2022 non-GAAP operating margin* of 17.8%, compared to 17.4% in Q4 2021 ● Q4 2022 GAAP EPS $0.58, compared to $0.36 in Q4 2021

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MERIT MEDICAL SYSTEMS INC updated its the year ended December 31, 2022 guidance (initiated).

Period: the year ended December 31, 2022
Guidance: initiated
Result: reported results

Exact text from the filing

On February 22, 2023, the Company issued a press release announcing its operating and financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

MERIT MEDICAL SYSTEMS INC filing history →

Source: SEC EDGAR

accession 0000856982-23-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.